ECOR electroCore

electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026

electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026

ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6, 2026.

Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:

Wednesday, May 6, 4:30 PM EDT

Dial-In: (646) 931-3860

Webinar ID: 856 5438 2775

Passcode: 895430

Registration Link:  to participate and ask questions on the call.

About electroCore, Inc.

electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit .

Contact:

ECOR Investor Relations

(973) 302-9253



EN
29/04/2026

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore TAC-STIM™ Named National Semifinalist in National Safety C...

electroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge ROCKAWAY, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that TAC-STIM™, its non-invasive vagus nerve stimulation (nVNS) product for human performance, has been named a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge (2026 Challenge), an annual initiative led by the National Safety Council (NSC) to identify technologies that can help prevent workplace injuri...

2h / 10m 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce First Quarter March 31, 2026, Financial Result...

electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026 ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, May 6, 4:30 PM EDTDial...

April 29, 2026 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Present at the Market Movers Investor Summit on May 5, ...

electroCore to Present at the Market Movers Investor Summit on May 5, 2026 ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers Investor Summit at the historic Bank of New York. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day. Event Details: Date: Tuesday, May 5, 2026Company Presentation: 12:20 PM ETLocation: 48 Wall Street, New York, NY (The original Bank of N...

April 28, 2026 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Product Line Featured in Documentary Underscoring the Expa...

electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced its participation in Hacking the Vagus Nerve, a documentary from the Healing Journeys series produced by The Root Cause Project and The Vagus Nerve Society. The film explores the role of the vagus nerve in regulating stress, mood, and immune function and features expert commentary from Peter S. St...

April 23, 2026 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Participate in the 25th Annual Needham Virtual Healthca...

electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026. Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day. DATE: April 15, 2026TIME: 2:15 pm ET Investors attending t...

April 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch